Homepage
PR Newswire
28-04-2017, 05:13 PM
We’re Getting Closer to Mass Production of Bones, Organs, and Implants
The hip bone’s connected to the thigh bone, and they’ll both be made by 3D printers.
by Adam Popescu
April 28, 2017, 2:59 AM GMT+8
From BloombergBusinessWeek
Medical researchers have been able to create certain kinds of living cells with 3D printers for more than a decade. Now a few companies are getting closer to mass production of higher-order tissues (bone, cartilage, organs) and other individually tailored items, including implants. This kind of precision medicine, treating patients based on their genes, environment, and lifestyle, could herald the end of long organ donor lists and solve other problems, too.
Organovo Holdings Inc.
Based in San Diego; 120 employees
What Organovo has successfully transplanted human liver tissue into mice to cure chronic liver failure. Pending the success of human trials, possible applications include the $3 billion market for inherited conditions such as hemophilia.
Who Ten-year-old Organovo, co-founded by bioprinting pioneer Gabor Forgacs, a professor at the University of Missouri, has received more than $100 million in funding for its development of 3D-printed tissues. The company uses bioprinted tissue to test drug toxicity and effectiveness on behalf of Big Pharma companies including Bristol-Myers Squibb Co. and Merck & Co.
Next Steps The company says it plans to begin human clinical trials by 2020. It’s also developing printable bone tissue for skeletal disease research and co-developing 3D-printed skin with L’Oréal SA.
More details in https://www.bloomberg.com/news/articles/...d-implants
The hip bone’s connected to the thigh bone, and they’ll both be made by 3D printers.
by Adam Popescu
April 28, 2017, 2:59 AM GMT+8
From BloombergBusinessWeek
Medical researchers have been able to create certain kinds of living cells with 3D printers for more than a decade. Now a few companies are getting closer to mass production of higher-order tissues (bone, cartilage, organs) and other individually tailored items, including implants. This kind of precision medicine, treating patients based on their genes, environment, and lifestyle, could herald the end of long organ donor lists and solve other problems, too.
Organovo Holdings Inc.
Based in San Diego; 120 employees
What Organovo has successfully transplanted human liver tissue into mice to cure chronic liver failure. Pending the success of human trials, possible applications include the $3 billion market for inherited conditions such as hemophilia.
Who Ten-year-old Organovo, co-founded by bioprinting pioneer Gabor Forgacs, a professor at the University of Missouri, has received more than $100 million in funding for its development of 3D-printed tissues. The company uses bioprinted tissue to test drug toxicity and effectiveness on behalf of Big Pharma companies including Bristol-Myers Squibb Co. and Merck & Co.
Next Steps The company says it plans to begin human clinical trials by 2020. It’s also developing printable bone tissue for skeletal disease research and co-developing 3D-printed skin with L’Oréal SA.
More details in https://www.bloomberg.com/news/articles/...d-implants
Specuvestor: Asset - Business - Structure.
